Friday, September 15, 2023 12:25:29 AM
2nd patient treated for inoperable pancreatic cancer. 1St was in Montreal
https://www.globenewswire.com/news-release/2023/09/14/2743253/0/en/Alpha-Tau-Treats-First-Patient-with-Advanced-Inoperable-Pancreatic-Cancer-at-Israel-s-Hadassah-Medical-Center.html
https://www.globenewswire.com/news-release/2023/09/14/2743253/0/en/Alpha-Tau-Treats-First-Patient-with-Advanced-Inoperable-Pancreatic-Cancer-at-Israel-s-Hadassah-Medical-Center.html
Recent DRTS News
- Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET • GlobeNewswire Inc. • 05/11/2026 11:00:00 AM
- Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma • GlobeNewswire Inc. • 05/08/2026 01:10:00 PM
- Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma • GlobeNewswire Inc. • 05/08/2026 01:00:00 PM
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute • GlobeNewswire Inc. • 05/07/2026 01:00:00 PM
- Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab • GlobeNewswire Inc. • 05/05/2026 01:14:32 PM
- Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 • GlobeNewswire Inc. • 05/04/2026 01:17:21 PM
- Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies • GlobeNewswire Inc. • 04/27/2026 01:01:00 PM
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel) • GlobeNewswire Inc. • 04/23/2026 01:02:00 PM
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial • GlobeNewswire Inc. • 04/23/2026 01:01:00 PM
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 • GlobeNewswire Inc. • 03/31/2026 01:15:00 PM
- Alpha Tau to Present at Sidoti March Virtual Small Cap Conference • GlobeNewswire Inc. • 03/16/2026 02:02:00 PM
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/09/2026 08:02:00 PM
- Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event • ACCESS Newswire • 01/23/2026 07:50:00 PM
- Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study • GlobeNewswire Inc. • 01/06/2026 02:00:00 PM
- Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation • AllPennyStocks.com • 01/05/2026 05:38:00 PM
- Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) • GlobeNewswire Inc. • 01/05/2026 02:00:00 PM
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference • GlobeNewswire Inc. • 12/18/2025 02:00:00 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University • GlobeNewswire Inc. • 12/09/2025 02:00:00 PM
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium • GlobeNewswire Inc. • 12/04/2025 02:00:00 PM
- Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer • GlobeNewswire Inc. • 12/02/2025 02:00:00 PM
- Alpha Tau to Participate in December Investor Conferences • GlobeNewswire Inc. • 12/01/2025 02:00:00 PM
- Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/20/2025 09:05:00 PM
- Alpha Tau to Participate at Jefferies Global Healthcare Conference in London • GlobeNewswire Inc. • 11/11/2025 01:30:00 PM
